A new study using CRISPR-Cas9 and long-acting slow-effective release antiretroviral therapy has reported the elimination of replication-competent HIV-1 DNA from the genomes of living animals for the first time.
Take a look at this month’s industry headlines including an FDA approval for a vaccine protecting against six diseases, positive clinical trial results for bacteraemia and dengue vaccines and new funding for CRSIPR-based antimicrobials.
In recent years, researchers have discovered the potential of CRISPR as an antimicrobial. In this blog post we explain the recent advances made in this field and the different approaches by which CRISPR can be used as a new weapon in the battle against antimicrobial resistance.
Researchers from Imperial College London have reported their recent success in using ‘gene drive’ technology to block female mosquito reproduction, resulting in the total collapse of caged populations of Anopheles gambiae in as little as 7–11 generations.
The gene-editing technique CRISPR could be used to detect infections, potentially revolutionizing the detection of viruses such as HPV and Zika, according to two papers recently published in Science.
A novel CRISPR–Cas9-based gene drive platform has been developed by researchers and may help us understand some of the genetic networks underlying virulence in fungal pathogen, Candida albicans.
CRISPR/Cas9 has been demonstrated to excise HIV-1 DNA from host tissues in vivo according to new research; this marks a major step towards a permanent cure for HIV infection.